Compare Incyte Corporation (INCY) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Okta, Inc. — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Okta, Inc. trades at $147.43 (market cap $26.13B). The key difference: Incyte Corporation and Okta, Inc. are close in size by market cap, and Okta, Inc. is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | OKTA | |
|---|---|---|
Market Cap | $24.54B | $26.13B |
Sector | Health | Technology |
52-Week High | $129.93 | $154.62 |
52-Week Low | $81.61 | $62.93 |
Enterprise Value | $20.04B | $23.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Okta trades at $147.43, down 2.22% today, with a bullish technical signal from moving averages but overbought RSI readings. The company achieved GAAP profitability in 2025 with $28M net income, marking a significant turnaround from prior losses. Recent earnings beats and the acquisition of Permiso Security for AI identity threat defense highlight growth momentum. Operating cash flow surged to $750M in 2025, supporting financial flexibility.
The outlook is positive with strong analyst support (73% buy ratings) and a consensus price target of $129.71, though the current price exceeds this. Risks include high valuation multiples (P/E 108.93) and competitive pressure from Microsoft. Revenue growth to $3.0B in 2026 forecasts sustained expansion, but investor caution is warranted near technical resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
